Avalo Therapeutics盘中飙升43.5% 皮肤病药物中期试验达主要终点

美股速递
May 06

Avalo Therapeutics Inc (AVTX) 股价在盘前交易时段大幅跃升43.5%,此前该公司宣布其针对皮肤病的在研药物已成功达成中期临床试验的主要目标。

这一积极数据显著提振了投资者信心,预示着该候选疗法在后续开发中具备良好潜力。受此消息影响,公司股价出现强劲反弹,市场反应热烈。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10